Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Q2 Revenues Increase 10 Percent

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that its revenues for the second quarter improved 10 percent year over year, paced by a 60 percent growth in grant revenues.

For the three months ended June 30, the South Easton, Mass.-based firm recorded total revenues of $357,736, up from $324,908 a year ago. While revenues from PCT products and services retreated 8 percent to $196,522 from $224,384, grant revenues increased to $161,214 from $100,524.

Pressure Bio recorded a net loss in the second quarter of $1.1 million, or $.10 per share, compared to a net loss of $509,692, or $.11 per share, a year ago.

The company used 11.5 million shares to calculate its net loss per share figure for the recently completed quarter, compared to 10.2 million shares in Q2 2012.

R&D spending came in at $260,408, up 2 percent from $256,307 a year ago. SG&A costs was up 36 percent to $871,525 from $642,188.

The firm finished the quarter with $113,663 in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.